Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer.

Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L, Nicol A, Clark PM, Farnell K, McCready R, Smellie J, Franklyn JA, John R, Nutting CM, Newbold K, Lemon C, Gerrard G, Abdel-Hamid A, Hardman J, Macias E, Roques T, Whitaker S, Vijayan R, Alvarez P, Beare S, Forsyth S, Kadalayil L, Hackshaw A.

N Engl J Med. 2012 May 3;366(18):1674-85. doi: 10.1056/NEJMoa1109589.

2.

rhTSH-aided low-activity versus high-activity regimens of radioiodine in residual ablation for differentiated thyroid cancer: a meta-analysis.

Ma C, Tang L, Fu H, Li J, Wang H.

Nucl Med Commun. 2013 Dec;34(12):1150-6. doi: 10.1097/MNM.0b013e328365ac05. Review.

3.

Recombinant human thyrotropin-aided versus thyroid hormone withdrawal-aided radioiodine treatment for differentiated thyroid cancer after total thyroidectomy: a meta-analysis.

Tu J, Wang S, Huo Z, Lin Y, Li X, Wang S.

Radiother Oncol. 2014 Jan;110(1):25-30. doi: 10.1016/j.radonc.2013.12.018. Review.

PMID:
24485353
4.

Recombinant human thyrotropin versus thyroid hormone withdrawal in radioiodine remnant ablation for differentiated thyroid cancer: a meta-analysis.

Fu H, Ma C, Tang L, Wu F, Liu B, Wang H.

Q J Nucl Med Mol Imaging. 2015 Mar;59(1):121-8. Review.

PMID:
24844252
5.

rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review.

Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F.

Endocr Relat Cancer. 2005 Mar;12(1):49-64. Review.

6.

Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer.

Ma C, Xie J, Liu W, Wang G, Zuo S, Wang X, Wu F.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008302. doi: 10.1002/14651858.CD008302.pub2. Review.

PMID:
21069705
7.

Low versus high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a meta-analysis of randomized controlled trials.

Du P, Jiao X, Zhou Y, Li Y, Kang S, Zhang D, Zhang J, Lv L, Patel R.

Endocrine. 2015 Feb;48(1):96-105. doi: 10.1007/s12020-014-0333-8. Review. Erratum in: Endocrine. 2015 Feb;48(1):106. Patel, Rajan [added].

PMID:
24997645
8.

Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review.

Jarzab B, Handkiewicz-Junak D, Wloch J.

Endocr Relat Cancer. 2005 Dec;12(4):773-803. Review.

9.

Recombinant human thyroid-stimulating hormone to stimulate 131-I uptake for remnant ablation and adjuvant therapy.

Sabra MM, Tuttle RM.

Endocr Pract. 2013 Jan-Feb;19(1):149-56. doi: 10.4158/EP12278.RA. Review.

PMID:
23186980
11.

Recombinant human thyroid-stimulating hormone as an alternative for thyroid hormone withdrawal in thyroid cancer management.

Chen MK, Doddamane I, Cheng DW.

Curr Opin Oncol. 2010 Jan;22(1):6-10. doi: 10.1097/CCO.0b013e3283339d5d. Review.

PMID:
19844179
12.

Recombinant thyroid-stimulating hormone in differentiated thyroid cancer.

Krausz Y, Uziely B, Nesher R, Chisin R, Glaser B.

Isr Med Assoc J. 2001 Nov;3(11):843-9. Review.

13.

Radioiodine post-surgical remnant ablation in patients with differentiated thyroid cancer: news from the last 10 years.

Molinaro E, Pieruzzi L, Viola D.

J Endocrinol Invest. 2012;35(6 Suppl):16-20. Review.

PMID:
23014069
14.

High versus low radioiodine activity in patients with differentiated thyroid cancer: a meta-analysis.

Valachis A, Nearchou A.

Acta Oncol. 2013 Aug;52(6):1055-61. doi: 10.3109/0284186X.2012.742959. Review.

PMID:
23193961
15.

[Clinical application of recombinant human thyroid-stimulating hormone in management of differentiated thyroid carcinoma].

Liu B, Kuang A.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2012 Jun;29(3):588-92. Review. Chinese.

PMID:
22826964
16.

131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review.

Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA.

J Clin Endocrinol Metab. 2007 Jan;92(1):28-38. Review.

PMID:
17032718
17.

Radioiodine therapy for patients with differentiated thyroid cancer after thyroidectomy: direct comparison and network meta-analyses.

Fang Y, Ding Y, Guo Q, Xing J, Long Y, Zong Z.

J Endocrinol Invest. 2013 Nov;36(10):896-902. doi: 10.3275/8998. Review.

PMID:
23723055
18.

Radioiodine remnant ablation: current indications and dosing regimens.

Haugen BR.

Endocr Pract. 2012 Jul-Aug;18(4):604-10. doi: 10.4158/EP12117.CO. Review.

PMID:
22849876
19.

The role of recombinant human thyrotropin for diagnostic monitoring of patients with differentiated thyroid cancer.

Sherman SI.

Endocr Pract. 2013 Jan-Feb;19(1):157-61. doi: 10.4158/EP12315.RA. Review.

PMID:
23435044
20.

The evolving use of radioiodine therapy in differentiated thyroid cancer.

Mayson SE, Yoo DC, Gopalakrishnan G.

Oncology. 2015;88(4):247-56. doi: 10.1159/000369496. Review.

PMID:
25503797
Items per page

Supplemental Content

Support Center